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Background: Venous leg ulcers impair quality of life significantly, with substantial costs to health
services. The aim of this study was to estimate the cost-effectiveness of interventional procedures
alongside compression therapy versus compression therapy alone for the treatment of chronic venous
leg ulceration.
Methods: A Markov decision analytical model was developed. The main outcome measures were
quality-adjusted life-years (QALYs) and lifetime costs per patient, from the perspective of the UK
National Health Service at 2015 prices. Resource use included the initial procedures, compression
therapy, primary care and outpatient consultations. The interventional procedures included superficial
venous surgery, endothermal ablation and ultrasound-guided foam sclerotherapy (UGFS). The study
population was patients with a chronic venous ulcer who were eligible for either compression therapy
or an interventional procedure. Data were obtained from systematic review and meta-analysis of RCTs.
Results: Surgery gained 0⋅112 (95 per cent c.i. −0⋅011 to 0⋅213) QALYs compared with compression
therapy alone, with a difference in lifetime costs of €−1330 (−3570 to 1262). Given the expected savings
in community care, the procedure would pay for itself within 4 years. There was insufficient evidence
regarding endothermal ablation and UGFS to draw conclusions.
Discussion: This modelling study found surgery to be more effective and less costly than compression
therapy alone. Further RCT evidence is required for both endothermal ablation and UGFS.
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Introduction
Chronic venous hypertension is the most common cause of
leg ulceration. The natural history is that of a continuous
cycle of healing and breakdown of skin tissues over decades,
causing considerable disability and impaired quality of life1.
It has been estimated that the UKNational Health Service
(NHS) manages 278 000 venous leg ulcers each year, at an
annual cost of €1024 million (£941 million; exchange rate
£1= €1⋅0882), mostly in primary care and community nurs-
ing services3. Moreover, with an ageing and increasingly
overweight population, the prevalence of venous ulceration
is likely to increase.
Compression with multilayer bandaging is standard ther-
apy, with the aim of improving venous return and reducing
venous hypertension until the ulcer has healed, followed
by graduated compression stockings for life to prevent
recurrence1,4. However, compression stockings are uncom-
fortable and patient compliance is poor.Many non-surgical
therapies have been proposed as alternatives or comple-
ments to compression to promote faster healing (manuka
honey, larval therapy, antibiotics, infrared light, ultra-
sound and many more), but with limited effectiveness1.
Cost-effectiveness analysis can aid decision-makers to
provide therapies that offer good value for money.
© 2018 The Authors. BJS Open published by John Wiley & Sons Ltd on behalf of BJS Society Ltd BJS Open
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Fig. 1 Markov model structure. The lead-in period is 6weeks,
during which initial therapy is undertaken. Subsequent cycles in
the long-term Markov model are 1 year. Transitions: a(T) is the
rate of healing at time T; b(1), b(2) etc. are the rates of recurrence
in the first, second, etc. year after healing; c(T) is the mortality
rate at time T; d is the rate of healing after recurrence. Tunnel
states for the fourth year and beyond after healing are included
in the model but not shown in the figure. See Appendix S4
(supporting information) for a full description of the model
states and transitions
Although many cost-effectiveness studies of non-surgical
therapies have been published5 so far, no cost-effectiveness
analyses of surgical procedures versus compression therapy
have been conducted. Recent reviews6,7 concluded that
superficial venous surgery alongside compression therapy
did not promote faster healing but did reduce recurrence.
Surgery requires a large upfront cost, but the benefits
in terms of fewer recurrences may take some years to
materialize. Decision models provide a framework for
comparing the risks and rewards of different options over
an appropriate time horizon. As well as superficial venous
surgery, several other interventional treatment options are
available, such as endothermal treatments (endovenous
laser ablation (EVLA) and radiofrequency ablation (RFA)),
and ultrasound-guided foam sclerotherapy (UGFS). These
have shown excellent results in the treatment of chronic
venous disease without ulceration1,8,9. However, there is
very little RCT evidence about their effectiveness in treat-
ing venous leg ulcers. One RCT10 has been conducted
for EVLA, which was found to be more effective than
compression for both healing and preventing recurrence.
This trial was included in the systematic review by Mauck
and colleagues7, but was considered to be of insufficient
methodological quality to be included in the Cochrane
review11. The review by Mauck et al.7 found one RCT for
UGFS, and concluded it was no better than compression
for healing; the trial12 did not report recurrence.
Table 1 Risk ratios estimated by a published systematic review7
Mean RR
Ulcer healing (RR>1 favours intervention)
Superficial venous surgery + compression
versus compression alone (5 RCTs)
1⋅04 (0⋅98, 1⋅09)
EVLA + compression versus compression alone
(1 RCT)
3⋅40 (1⋅65, 6⋅98)
UGFS + compression versus compression
alone (1 RCT)
0⋅86 (0⋅58, 1⋅28)
Recurrence (RR<1 favours intervention)
Superficial venous surgery + compression
versus compression alone (2 RCTs)
0⋅67 (0⋅41, 1⋅10)
EVLA + compression versus compression alone
(1 RCT)
0⋅03 (0⋅00, 0⋅58)
Values in parentheses are 95 per cent confidence intervals. RR, risk ratio;
EVLA, endovenous laser ablation; UGFS, ultrasound-guided foam
sclerotherapy.
The aim of this study was to estimate the cost-
effectiveness of interventional procedures alongside
compression therapy versus compression therapy alone for
treatment of chronic venous leg ulcers using a decision
model. The primary (base case) study compared superficial
venous surgery with compression. Scenario analyses incor-
porated the limited evidence from other interventional
procedures, including EVLA10 and UGFS12.
Methods
Decision model
Model overview
Analyses were performed from the perspective of the UK
NHS and Personal Social Services at 2015–2016 prices.
Currency conversion was made using purchasing power
parities, at a rate of £1= €1⋅0882. Discounting at 3⋅5 per
cent per year was applied for costs and QALYs (varied in
sensitivity analysis)13. The study was reported according to
guidelines for economic evaluation14.
A Markov decision model was used to carry out the
analyses. A decision model is a mathematical tool that
links together the different types of evidence that might
be of interest to decision-makers in a coherent structure.
In the context of venous leg ulcers, the relevant outcomes
include the effectiveness of the treatments (in terms of
healing and recurrence), the costs over the short and long
term, and the impact of the treatments and the disease on
health-related quality of life (HRQoL). Clinical trials form
the evidence base for such models, yet RCTs usually have
follow-up limited to a few years. As venous leg ulceration
is a chronic condition, and can recur several times, a long
decision horizon is appropriate. Decision models provide
a framework for extrapolating outcomes beyond the trial
reporting period.
© 2018 The Authors. www.bjsopen.com BJS Open
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Fig. 2 Proportion of patients with healed ulcer observed in the
ESCHAR trial21 (compression therapy alone arm): observed data
and proportion predicted using the Weibull function
Population
The population of this study was patients with a chronic
venous leg ulcer whowould be eligible for an interventional
procedure or compression therapy alone. A chronic venous
leg ulcer is defined as an open lesion between knee and
ankle joint that has remained unhealed for at least 6weeks
and occurs in the presence of venous disease1,9. Patients are
usually elderly. In the ESCHAR study15, for example, the
mean age was 73 (i.q.r. 60–80) years, and around 60 per
cent of the patients were women.
Interventions and comparators
The comparator was compression therapy alone. There
are many variations of compression therapy16, but in this
study it was assumed that multilayer bandaging aiming
to provide 40mmHg of compression at the ankle was
used until the ulcer had healed, followed by the use of
compression stockings for life to prevent recurrence. In the
interventional procedure arm, compression therapy was
applied as in the comparator arm, but, in addition, surgery
was used to treat the superficial venous reflux as soon as
possible.
Health states
The two main effectiveness outcomes captured in the
model are ulcer healing and recurrence. Fig. 1 shows the
model structure in the form of an influence diagram. Full
details of the model structure are described in Appendix S1
(supporting information). There is a lead-in period repre-
senting the time from initiating therapy to first follow-up
Table 2 Rates of healing and recurrence with compression
therapy used in the model, based on ESCHAR21
Event rate in the model
Data from ESCHAR
(compression therapy arm)
Rate of ulcer healing with
compression therapy
65% healed after 6months and
89% healed after 3 years
Rate of recurrence with
compression therapy
28% recurred after 1 year and
56% recurred after 4 years
Rate of healing after
recurrence
89% healed 3 years after onset
of recurrence
(6weeks), during which compression bandaging is applied,
diagnosis of venous ulcer is confirmed, and initial surgery
is undertaken, depending on the protocol of that treatment
arm. This period includes recovery time from surgery.
Patients then enter a ‘long-term’ state transition Markov
model17 with a cycle length of 1 year. The model allows
ulcers to heal and recur, perhaps several times over the
lifetime. The starting age was 73 years, and the model esti-
mated outcomes up to 100 years of age. Rates of healing
and rates of recurrence can vary over time. Mortality rates
increase with age, but are assumed not to differ between
treatments or between states. Rates are obtained from the
literature and are converted to annual transition probabil-
ities using a published method18 (Appendix S2, support-
ing information). The model was constructed in Excel®
(Microsoft, Redmond, Washington, USA). A copy is made
available to researchers under a CC BY 4.0 licence (https://
doi.org/10.17632/7634sv27zp.1).
Parameter estimates for the model
Relative treatment effects for healing and recurrence
A clinical literature review7 estimated the relative treat-
ment effects for healing for surgical procedures versus com-
pression therapy. The systematic review included both
observational studies and RCTs, but in the present study
only results obtained from RCT data were included in the
model, as the observational studies were assessed as of low
methodological quality with a high risk of bias7. The results
of the meta-analysis of RCT data are shown in Table 1.
Superficial venous surgery did not promote faster healing
than compression bandaging alone (risk ratio (RR) 1⋅04, 95
per cent c.i. 0⋅98 to 1⋅09). The clinical review7 found that
superficial venous surgery led to fewer recurrences than
compression alone, although the overall (pooled) result did
not reach statistical significance (RR 0⋅67, 0⋅41 to 1⋅10).
The evidence on EVLA was limited to a single RCT11,
which found substantially faster healing with EVLA
than for compression (RR 3⋅40, 95 per cent c.i. 1⋅65 to
6⋅98). Furthermore, in the 22 patients with a healed ulcer
© 2018 The Authors. www.bjsopen.com BJS Open
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Fig. 3 Freedom from recurrence observed in the ESCHAR trial21
(compression therapy alone arm): observed data and proportion
predicted using the Weibull function
following EVLA, there were no cases of recurrence of
ulceration, whereas with compression therapy alone there
were four recurrences in nine healed patients (RR 0⋅03,
0⋅00 to 0⋅58)10. However, the Cochrane group11 excluded
this study for poor methodological quality, and thus it was
not included in the base case model.
UGFS did not show more rapid healing than compres-
sion (RR 0⋅86, 95 per cent c.i. 0⋅58 to 1⋅28), although the
trial12 was unable to recruit the required number of patients
and so these results should be interpreted with caution.
The RCT followed up patients only to 24weeks, which was
inadequate to assess recurrence. Although case series19,20
have suggested recurrence rates might be similar to those
following surgery, these studies presented a high risk of bias
and are therefore not sufficient evidence for the model.
Given the lack of strong evidence of any benefit, it was
assumed that recurrence rates after UGFS are the same as
for compression.
Rate of healing with compression therapy alone
The ESCHAR trial21 was a large, UK-based, publicly
funded RCT with a long follow-up; these results are used
to inform the natural history of venous leg ulcers with
compression therapy (the comparator in the model). Fig. 2
shows the observed proportion of patients with a healed
ulcer at 6months (66 per cent) and 3 years (89 per cent) in
the compression therapy-alone arm of the trial21. A con-
stant rate (exponential survival) model is inappropriate for
these data. The rate of healing slowed over time: most
ulcers healed within the first 6months with compression
therapy, but a small proportion of patients had very long
healing times. This time-dependent pattern of healing can
be modelled with a Weibull distribution (Table 2; Appendix
S2, supporting information). The clinical trial did not
report any measure of statistical uncertainty (such as stan-
dard error) associated with the proportion healed, so the
corresponding standard error of the Weibull parameters
cannot be estimated. However, given the large sample size
of ESCHAR (257 patients randomized to compression
alone and only 27 lost to follow-up), the statistical error
was likely to be very small. It was assumed for the prob-
abilistic sensitivity analysis that the standard errors of the
Weibull parameters were 10 per cent of the means.
Rate of recurrence with compression therapy alone
The ESCHAR trial21 found the probability of recurrence
after compression therapy was 28 per cent after 1 year and
56 per cent after 4 years (Fig. 3). The rate of recurrence
of venous ulceration slowed over time: recurrence was
more likely in the first year than in the second year after
healing, and so on. Therefore, the rate of recurrence
used in the model was also estimated from these data
using a Weibull distribution. The ESCHAR data were
not reported exactly in the format required by the model.
The model requires the time from healing to recurrence,
whereas the clinical trial reported time from randomiza-
tion to recurrence (Appendix S1, supporting information).
However, in practice, the difference is minor. One-third
of ulcers in the ESCHAR trial were already healed at
baseline, and two-thirds of the remainder had healed by
6months. Hence it is assumed that the ESCHAR data
were approximately indicative of the recurrence rate from
time of healing.
Mortality
The ESCHAR trial21 found that 17 per cent of patients had
died by 3 years, with no statistically significant difference
between groups, or any mortality associated with surgery.
This rate of mortality was greater than would be expected
in the general population of the same age, reflecting the
greater co-morbidity associated with venous disease. Mor-
tality rates in the model were based on life-table estimates
from a general population of the same age22, but calibrated
upwards to coincide with the average mortality observed in
ESCHAR.
Resource use and unit costs
NHS resources included two bandage changes per week
(40-min community nurse home visit23,24 and wound care
© 2018 The Authors. www.bjsopen.com BJS Open
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Table 3 Resource use and unit costs used in the model
No. of patients
in sample Use per patient* Unit cost
Total cost
per patient* References
Compression therapy related
Bandage (Coban™ 2) +
dressing (UrgoTul®)
Applied by community
nurse twice-weekly
until healing (40-min
home visit)
€8⋅80 (bandages) +
€1⋅63 (dressing) +
nurse visit €73 per h
€118 per week 23–26
Compression stockings Applied after healing,
changed every
3months
€34⋅02 €34 every
3months
25
Other healthcare related to
ulcer while healing†
GP consultation 169 2⋅32(7⋅60) €44 per visit €103 per year 23, 26
Nurse consultation in GP
surgery (22min)
169 25⋅32(35⋅29) €61 per h €566 per year 23, 26
Hospital outpatient visits‡ 169 8⋅84(19⋅01) €77 per visit €683 per year 23, 26
Cost of interventional
procedures
Surgery 195 €997(448) 27
EVLA 183 €802(222) 27
UGFS 182 €267(175) 27
*Values are mean or mean(s.d.); †number of visits per year; ‡without ultrasound imaging. Coban™ 2 (3M, St Paul, Minnesota, USA); UrgoTul® 5 × 5 cm
(Urgo Medical, Chenôve, France). GP, general practitioner; EVLA, endovenous laser ablation; UGFS, ultrasound-guided foam sclerotherapy.
consumables25), general practitioner and primary care
nurse consultations associated with the ulcer23,24,26, hos-
pital outpatient visits24,26 and interventional procedures27
(Table 3). Compression stockings are used to prevent recur-
rence after the ulcer has healed25. It was assumed there
were no other ulcer-related healthcare expenses once the
ulcer had healed. Costs of surgery, UGFS and EVLA
procedures were obtained from the CLASS (Comparison
of LAser, Surgery and foam Sclerotherapy) study27. The
prices of the catheter, laser fibre and other kit for EVLA
in the CLASS study were estimated from prices paid by
the lead centre, €278; these are usually negotiated with the
supplier.
Health-related quality of life
Clegg and Guest28 estimated the mean HRQoL (utility)
associated with an unhealed venous leg ulcer to be 0⋅64
(95 per cent c.i. 0⋅60 to 0⋅68) by standard gamble from 200
members of the general public (some of whomhad personal
experience of ulcers). They assumed that, once the ulcer
had healed, patients returned to full health for a person of
that age.
Carradice and co-workers29 reported HRQoL and time
to return to normal activities after varicose vein surgery
and EVLA. Time to return to work or normal activity was
longer after surgery than EVLA (14 versus 4 days respec-
tively; P< 0⋅001) and both procedures resulted in reduced
HRQoL at 1week compared with baseline (reduction in
HRQoL measured by the EQ-5D™ (EuroQol Group,
Rotterdam, The Netherlands) index of 0⋅05; P= 0⋅024). In
the model, it was assumed that the reduction in HRQoL
was 0⋅05, lasting for 2weeks after surgery and for 4 days
after EVLA.
Cost-effectiveness analysis
The results of the analyses were presented as estimates of
mean total cost per patient and mean QALY for each ther-
apy option. The following univariable sensitivity analyses
were conducted to test the robustness of the results to alter-
native input data: no difference between surgery and com-
pression in time to healing; no difference between surgery
and compression in time to recurrence; an unhealed ulcer
causes much higher detriment to HRQoL (utility 0⋅5); an
unhealed ulcer causes little detriment to HRQoL (util-
ity 0⋅9); only one bandage change per week; discount
rate of 0 per cent and discount rate of 6 per cent per
year.
Probabilistic sensitivity analyses were conducted using
1000 Monte Carlo simulations30. Appendix S3 (supporting
information) shows the distributions of model parameters
used in the probabilistic sensitivity analysis. Analysis of
co-variance was used to identify the input parameters that
most explained the overall variance in difference in costs
andQALYs predicted by the model30. Exploratory analyses
were also conducted to evaluate the cost-effectiveness of
EVLA and UGFS, using the effectiveness estimates from
Viarengo et al.10 and O’Hare and Earnshaw12.
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Table 4 Results of base case analysis of surgery versus compression only and exploratory analyses with endovenous laser ablation and
ultrasound-guided foam sclerotherapy
Discounted total QALY per patient Discounted total lifetime cost per patient (€)
Mean Mean difference from compression Mean Mean difference from compression
Base case analysis
Compression only 5⋅878 0⋅000 (reference) 19 046 0⋅000 (reference)
Surgery 5⋅990 0⋅112 (−0⋅011, 0⋅213) 17 717 −1330 (−3570, 1262)
Exploratory analyses of
the cost-effectiveness of
other interventions*
UGFS 5⋅789 −0⋅089 (−0⋅364, 0⋅121) 21 104 2057 (− 2197, 7660)
EVLA 6⋅653 0⋅775 (0⋅476, 1⋅033) 4027 −15020 (−20620, −9171)
Values in parentheses are 95 per cent confidence intervals. *Based on results of RCTs10,12 of low methodological quality. QALY, quality-adjusted life-year;
UGFS, ultrasound-guided foam sclerotherapy; EVLA, endovenous laser ablation.
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Fig. 4 Predicted total mean cost per patient over the lifetime (undiscounted, euros). Compression stockings are used to prevent
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unhealed leg ulcer. General practitioner (GP) and other nursing are visits to primary care related to the unhealed leg ulcer. Dressings
and bandages are assumed to be changed twice-weekly by a district nurse until the wound is healed. The initial treatment is surgery,
ultrasound-guided foam sclerotherapy (UGFS) or compression only
Results
Base case analysis
The results of the cost-effectiveness model are shown in
Table 4. Surgery was more effective and less costly over the
lifetime of the patient. Surgery gained 0⋅112 (95 per cent
c.i. −0⋅011 to 0⋅213) QALYs compared with compression
therapy alone, with a difference in lifetime costs of €−1330
(−3570 to 1262). The (undiscounted) cost of compression
therapy over the lifetime of a patient with a venous leg
ulcer was more than €22 000, of which over 75 per cent
was the cost of bandaging and nursing while the ulcer
healed. Surgery reduced considerably the probability of
recurrence, and hence was cost-saving overall (Fig. 4). The
savings in community care would begin to outweigh the
initial cost of the surgical procedure after 4 years (Fig. S1,
supporting information). Fig. 5 shows the proportion of
patients predicted by the model to have a healed ulcer at
each year after start of therapy.
Univariable and probabilistic sensitivity analysis,
and analysis of co-variance
Univariable sensitivity analyses alter one input to the
model, leaving the others the same as the base case (Table 5).
In one sensitivity analysis, assuming there was no difference
© 2018 The Authors. www.bjsopen.com BJS Open
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Fig. 5 Estimated proportion of patients with a healed leg ulcer
following surgery or compression therapy alone
in recurrence rates between treatments, surgery was both
more effective and more expensive than compression ban-
daging, and the incremental cost-effectiveness ratio was
€27 647 per QALY. Surgery was still more effective in the
model than compression alone, because the base case RR
for healing was slightly in favour of surgery, although the
effect was not statistically significant (RR 1⋅04, 95 per cent
c.i. 0⋅98 to 1⋅09). Evidently, if surgery had no positive effect
on either healing or recurrence, compression would be the
cheaper and more effective option.
The probabilistic sensitivity analysis found that, using the
base case inputs to the model, surgery had a probability
in excess of 0⋅90 of being the most cost-effective option
at any cost-effectiveness threshold. Analysis of co-variance
indicated that the RR for recurrence is the input parameter
that explains most (over 86 per cent) of the overall uncer-
tainty in incremental cost and incremental QALYs between
surgery and compression therapy alone (Table S1, support-
ing information).
Exploratory analysis of EVLA and UGFS
for treating venous leg ulcers
Exploratory analysis indicated that, if the RCT estimates
of healing and recurrence rates from Viarengo et al.10 and
O’Hare and Earnshaw12 were accurate, EVLA would be
both more cost-saving andmore effective than surgery, and
UGFS would be more costly and less effective (Table 4).
Validation of the model
It is important to validate a model by comparing pre-
dictions against observed data. The model predicted the
death of 17 per cent of patients (the same in each treat-
ment group), and the mean ulcer-free time was 89weeks
in the surgery group versus 83weeks with compression
therapy alone at 3 years (after half-cycle correction). The
ESCHAR study found that 16 per cent of patients in the
compression-only group died and 19 per cent in the surgery
group (P= 0⋅245), and the ulcer-free time at 3 years was
100weeks with surgery and 85weeks with compression
alone. The model predictions are not exactly the same as in
the ESCHAR trial, because the model incorporates clinical
Table 5 Results of univariable sensitivity analyses
Sensitivity analyses Most effective option
Option with
lowest cost
ICER (surgery
versus compression)
Base case Surgery Surgery Surgery dominant
RR for healing after
surgery versus
compression is 1⋅04
(0⋅98, 1⋅09)
RR for healing: 1 Surgery Surgery Surgery dominant
RR for recurrence after
surgery versus
compression is 0⋅67
(0⋅41, 1⋅10)
RR for recurrence: 1 Surgery Compression €27 647 per QALY
EQ-5D™ score associated
with unhealed ulcer is
0⋅64 (0⋅60, 0⋅68)
EQ-5D™ score: 0⋅5 Surgery Surgery Surgery dominant
EQ-5D™ score associated
with unhealed ulcer is
0⋅64 (0⋅60, 0⋅68)
EQ-5D™ score: 0⋅9 Surgery Surgery Surgery dominant
Two bandage changes per
week until ulcer healed
1 bandage change per
week until ulcer healed
Surgery Surgery Surgery dominant
Discount rate 3⋅5% 0% or 6% Surgery Surgery Surgery dominant
Values in parentheses are 95 per cent confidence intervals. ICER, incremental cost-effectiveness ratio; RR, risk ratio; QALY, quality-adjusted life-year.
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risk evidence from diverse sources (the ESCHAR trial and
meta-analysis of RRs).
Discussion
This study estimated the cost-effectiveness of compres-
sion therapy alone versus interventional procedures (along-
side compression therapy) for the treatment of venous leg
ulcers. The main finding was that surgery is the most effec-
tive and least costly treatment option. Venous leg ulcers
are very costly for health services to treat and, by prevent-
ing recurrence, surgery would pay for itself within 4 years,
compared with compression therapy alone. The results
are robust to alternative assumptions. If the outcomes of
the study by Viarengo and colleagues10 were confirmed,
EVLA would be very cost-effective. However, given the
risk of bias in that RCT, no definitive conclusions can yet
be reached.
This is the first cost-effectiveness analysis to compare
surgical procedures with compression therapy for venous
leg ulcers. The data for RRs were based on a system-
atic review of RCTs7, which are usually considered to be
the most valid form of evidence. At the time of publi-
cation of the systematic review7, the ESCHAR RCT21
reported substantially fewer recurrences after surgery at
4 years, whereas van Gent and co-workers31 showed no
difference in recurrence at 2 years. However, recently pub-
lished long-term follow-up from the latter study showed
that surgery almost halved the probability of recurrence
at 10 years32, corroborating the outcome of the ESCHAR
trial21. Nevertheless, these data should be interpreted cau-
tiously. The systematic reviewers rated the RCTs as hav-
ing a moderate risk of bias, mainly due to omissions in
the reporting of the method of randomization, blind-
ing, how missing data were handled, and the funding
source.
In some of the older RCTs, such as ESCHAR, many
patients in the interventional arm either did not have
surgery or underwent procedures that would be considered
suboptimal bymodern endovenous standards33. Themodel
assumes patients are maintained on lifetime compression
therapy after interventional procedures to avoid recur-
rence. It has been suggested33 that some patients could be
managed successfully without compression after interven-
tional procedures. However, these considerations would
make interventional procedures even more cost-effective
than compression alone.
One common treatment modality not included in this
study is endovenous RFA. This was owing to a lack of
published randomized trials using RFA in patients with
chronic venous ulcers. However, the mode of action and
published technical success rates are comparable to those
for EVLA34,35, leading some bodies (including the UK
National Institute for Health and Care Excellence) to
describe EVLA and RFA together as endovenous thermal
ablation procedures36.
No other cost-effectiveness analyses have compared
interventional procedures with compression therapy.
VenUS I estimated the annual cost of compression therapy
with multilayer bandaging to be €1412 (95 per cent c.i.
1291 to 1600) (£1298, 1187 to 1471) at 2001 prices16.
The present study suggests the first-year cost of com-
pression therapy is closer to €4200 at 2015–2016 prices.
Inflation accounts for one-quarter of the difference37,
and the remainder may be due to the assumption of
two bandage changes per week, with no washing and
reuse of bandages. Sensitivity analysis using one bandage
change per week, rather than two, did not change the
main findings.
Further research would be worthwhile in several areas.
First, the analysis indicated that the RR for recurrence
is the most influential parameter in this decision. There
may be different impacts by subgroups. ESCHAR found
that the greatest relative benefit of surgery tended to be
in patients with isolated superficial venous reflux. Fur-
ther RCTs, or meta-analysis of existing RCTs using indi-
vidual patient data, might investigate whether differing
patterns of venous reflux or other factors influence out-
comes. Second, further RCTs should compare interven-
tional procedures with one another as well as, or instead
of, compression therapy. Endothermal procedures might
be extremely effective for the treatment of venous leg
ulcers, but this evidence is still weak. There is currently
an ongoing RCT comparing early endovenous ablation
(EVLA, RFA or UGFS) with delayed endovenous abla-
tion for the treatment of venous leg ulcers (Early Venous
Reflux Ablation (EVRA) trial; ISRCTN02335796). Once
finalized, these results will inform the optimal use and
timing of endovenous procedures in the management
of leg ulcers.
The results of this study should inform the next gen-
eration of clinical guidelines for venous leg ulcers. In a
very challenging economic climate, the delivery of surgical
procedures to patients with chronic venous ulcers would
require significant changes to current pathways of care.
These patients usually present to and are managed by com-
munity nursing teams in the very peripheries of health-
care systems, whereas surgery, specialist venous scanning
and endovenous interventions are usually delivered in sec-
ondary care environments. Published guidelines should be
supported by plans for implementation and robust audit
frameworks.
© 2018 The Authors. www.bjsopen.com BJS Open
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